

Pharmacy Drug Policy Checklist

Criteria

Criteria for Coverage for West Syndrome (infantile spasms)		
	1.1 Documentation of West Syndrome	
	1.2 Documentation showing that member is less than 2 years of age	
	1.3 Approval period: 4 week treatment regimen within a 6 month approval duration	
	1.4 Reauthorization requires documentation that member shown substantial clinical benefit from therapy	

Excluded Diagnoses		
	1.5 The use of Acthar for the treatment of acute exacerbations of multiple sclerosis is not considered medically necessary.	
	 Acthar gel showed no clinical benefit, greater number of adverse effects, and required longer duration of treatment vs. IV methylpredinisolone 	
	 Acthar gel administered either intramuscularly or subcutaneously at a dose of 80 U/day for 5 days. No significant treatment difference was observed. No direct comparison to methylprednisolone performed. 	
	 Health Alliance does not consider known adverse events associated with corticosteroid use to be a contraindication preventing future use. 	
	1.6 FDA labeling suggests that H.P. Acthar may be useful in the following conditions, but it is not FDA- indicated. H.P. Acthar is unproven and not medically necessary in the following situations	
	Testing of adrenocortical function	
	 Musculoskeletal Disorders: ? As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis. 	
	• Skin Diseases: ② During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis).	
	 Dermatologic Diseases: ? Severe erythema multiforme, Stevens-Johnson syndrome, atopic dermatitis 	
	Serum sickness	
	• Eye Diseases: ? Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis; anterior segment inflammation.	
	• Lung Diseases: ? Symptomatic sarcoidosis.	
	• Diuresis in nephrotic syndrome: Criteria Statement of the Policy References ? To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the	

• Any indication outside of infantile spasms CPT Codes HCPCS Codes J0801 Injection,

idiopathic type or that due to lupus erythematosus.

corticotropin (acthar gel)